4//SEC Filing
Shah Jatin 4
Accession 0001209191-20-057052
CIK 0001503802other
Filed
Nov 3, 7:00 PM ET
Accepted
Nov 4, 8:16 PM ET
Size
9.4 KB
Accession
0001209191-20-057052
Insider Transaction Report
Form 4
Shah Jatin
EVP, Chief Medical Officer
Transactions
- Sale
Common Stock
2020-07-15$19.46/sh−589$11,462→ 43,229 total - Exercise/Conversion
Common Stock
2020-07-11+2,413→ 43,172 total - Exercise/Conversion
Restricted Stock Units
2020-07-11−2,413→ 7,237 total→ Common Stock (2,413 underlying)
Footnotes (4)
- [F1]Restricted stock units convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.
- [F2]This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
- [F3]Includes 646 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on October 31, 2020.
- [F4]On July 11, 2019, the reporting person was granted 9,650 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. 25% of the restricted stock units vested on July 11, 2020. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date.
Documents
Issuer
Karyopharm Therapeutics Inc.
CIK 0001503802
Entity typeother
Related Parties
1- filerCIK 0001782186
Filing Metadata
- Form type
- 4
- Filed
- Nov 3, 7:00 PM ET
- Accepted
- Nov 4, 8:16 PM ET
- Size
- 9.4 KB